[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567087":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"short-term glucocorticoid monotherapy","PLACEBO_COMPARATOR","Oral prednison starts at 0.6-0.8mg\u002Fkg\u002Fd, then tapered and withdrawal in 6 months.",[13],"Drug: prednison",{"label":15,"type":16,"description":17,"interventionNames":18},"short-term glucocorticoid combined with Mycophenolate mofetil","EXPERIMENTAL","Oral prednison starts at 0.6-0.8mg\u002Fkg\u002Fd, then tapered and withdrawal in 6 months. Oral Mycophenolate mofetil 0.75g bid for 6 months.",[13,19],"Drug: Mycophenolate mofetil",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","prednison",[15,9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Mycophenolate mofetil","Oral Mycophenolate mofetil 0.75g bid for 6 months.",[15],[31],{"name":32,"affiliation":5,"role":33},"Wen Zhang, MD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Linyi Peng, MD","CONTACT","8615810395901","drpenglinyi@163.com",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Beijing","Beijing Municipality","100050","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55,56],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},{"name":32,"role":37,"phone":25,"phoneExt":25,"email":25},{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Wen Zhang","Professor","100567087","short-term-glucocorticoid-combined-with-mmf-for-igg4-rd-100567087",false,"NCT06663618","Short-term Glucocorticoid Combined with MMF for IgG4-RD","Comparison of Short-term Glucocorticoid Monotherapy and Short-term Glucocorticoid Combined with Mycophenolate Mofetil in the Treatment of IgG4 Related Disease","Inclusion Criteria:\n\n1. 18-80 years old;\n2. All patients must meet the comprehensive diagnostic criteria of IgG4-RD revised in Japan in 2020 or the classification criteria of IgG4-RD formulated by ACR\u002FEULAR in 2019;\n3. Active IgG4-RD (at least one organ has an IgG4-RD reaction score \\>=2 at the time of enrollment.)；\n4. No previous medication or recurrence after withdrawal.\n\nExclusion Criteria:\n\n1. Combined with other autoimmune diseases as the main diagnosis.\n2. Pregnant or lactating women\n3. Patients with malignant tumor\n4. Active bacterial, fungal, viral or mycobacterial infections.\n5. Severe complications of important organs, and the expected survival time is less than 6 months.","ALL","18 Years","80 Years",{"count":72,"type":73},63,"ESTIMATED","INTERVENTIONAL",[76],"NA","Comparison of short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease",[79],"IgG4-related Disease",[81],"IgG4-related disease","2024-10-26",{"date":84,"type":85},"2024-10-29","ACTUAL",{"date":87,"type":85},"2023-09-01",{"date":89,"type":73},"2025-09-01",{"name":59,"class":6},1]